Aberrant gene expression is a hallmark of cancer. Over the years, several therapies have been developed to reprogram tumor tissues, i.e., induction of differentiation, transdifferentiation, reconstitution of immunosurveillance, and activation of alternative tumor cell death.

Tumor reprogramming techniques can also provide novel activity profiles for approved targeted therapies (drug repurposing) and control the metastatic process, tumor repopulation, resistance, and genetic/molecular-genetic tumor cell heterogeneity (M-CRAC).

The nuclear receptor (NR) family plays a key role in regulating multiple cellular processes and, if aberrantly activated, contributes to tumorigenesis. Nuclear receptor agonists or antagonists are widely used for the treatment of hormone-sensitive tumors and hematologic malignancies and new ligands are currently under development to target different NRs, such as peroxisome-proliferator receptor α and γ (PPAR α/γ) agonists.

This Research Topic aims to provide an extensive overview of classical therapies targeting NRs and the increasing repertoire of drugs facilitating transcriptional modulation with the ultimate goal of summarizing these tumor tissue reprogramming approaches as a specific treatment paradigm for systemic tumor therapy.

Potential topics include, but are not limited to:
- novel transcriptional modulation strategies to counteract cancer drug-resistance
- drug repurposing by tumor tissue editing
- tumor reprogramming to achieve tumor systems states associated with clinically meaningful tumor control

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Submit your idea

Impact

Frontiers in Oncology

Participating Journals

Impact